Diagnosis and treatment of chronic pulmonary aspergillosis: clinical guidelines of European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society

Chronic pulmonary aspergillosis (CPA) is infrequent respiratory disease which is difficult for diagnosis and can complicate other respiratory diseases and conditions. Currently, there are about 240,000 CPA patients in Europe. The most prevalent variant of CPA is chronic cavitary pulmonary aspergillosis (CCPA) which could progress to chronic fibrosing pulmonary aspergillosis (CFPA) when is untreated. Aspergillus nodules and single aspergilloma are less frequent clinical variants of this disease. All clinical variants of aspergillosis could be found in nonimmunocompromised patients with different underlying pulmonary disorders. Subacute invasive pulmonary aspergillosis, which was referred to as chronic necrotising pulmonary aspergillosis, is the most rapidly progressive clinical variant of the infection (< 3 months); it is typically diagnosed in moderately immunocompromised patients and should be treated as invasive aspergillosis. Diagnosis and management of CPA patients were previously described in sporadic guidelines. Due to this, expert group have been convened to develop clinical, radiological and microbiological guidelines. Diagnosis of CPA requires a combination of the following criteria existing for 3 months or more: one or more cavities in the lungs with or without fungal mass inside or nodules found on radiological examination; direct evidence of Aspergillus infection (using microscopic examination or biopsy culturing) or immunological response to Aspergillus spp. and exclusion of alternative diseases. Antibodies against Aspergillus spp. (precipitins) are increased in > 90% of patients. Aspergilloma should be resected if technically possible; videoassisted thoracic surgery is preferable. Chronic cavitary pulmonary aspergillosis requires longterm oral antifungal therapy to improve the patients' health and respiratory symptoms, to arrest haemoptysis and prevent the disease progression. Azole serum concentration and drug interaction should be thoroughly monitored to avoid toxic effects. Haemoptysis could be arrested using therapy with tranexamic acid or bronchial artery embolization; surgical resection of the lung is rarely required. Haemoptysis could indicate therapeutic failure and / or resistance to antifungals. Patients with a single Aspergillus nodule need antifungal therapy only if surgical resection is impossible. Antifungal therapy could be beneficial in patients with multiple Aspergillusis nodules; these patients need careful followup.

1. Bennett J. On the parasitic vegetable structures found growing in living animals. Trans Royal Soc. Edinburgh. 1842; 15: 277–279.

2. Kelmenson V.A. Treatment of pulmonary aspergillosis. Dis. Chest. 1959; 36: 442–443.

3. Deve F. Une nouvelle forme anatomoradiologique mycose pulmonaire primitive. Le megamycetome intrabron chiectasique [A new anatomical shape radiological primary pulmonary fungal infection. The megamycetoma intrabronchiectasique]. Arch. Med. Chir. Appar. Respir. 1938; 13: 337.

4. Finegold S.M., Will D., Murray J.F. Aspergillosis: a review and report of 12 cases. J. Med. 1959; 27: 463–482.

5. Longbottom J.L., Pepys J., Clive F.T. Diagnostic precipitin test in Aspergillus pulmonary mycetoma. Lancet. 1964; 1: 588–589.

6. Gefter W.B., Weingrad T.R., Epstein D.M. et al. «Semiinvasive» pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung. Radiology. 1981; 140: 313–321.

7. Binder R.E., Faling L.J., Pugatch R.D. et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinicalentity. Medicine. 1982; 61: 109–124.

8. Battaglini J.W., Murray G.F., Keagy B.A. et al. Surgical management of symptomatic pulmonary aspergilloma. Ann. Thorac. Surg. 1985; 39: 512–516.

9. Daly R.C., Pairolero P.C., Piehler J.M. et al. Pulmonary aspergilloma. Results of surgical treatment. J. Thorac. Cardiovasc. Surg.1986; 92: 981–988.

10. Denning D.W., Riniotis K., Dobrashian R. et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin. Infect. Dis. 2003; 37 (Suppl. 3): S265–S280.

11. Godet C., Philippe B., Laurent F. et al. Chronic pulmonary aspergillosis: an update on diagnosis and treatment. Respiration. 2014; 88: 162–174.

12. Hope W.W., Walsh T.J., Denning D.W. The invasive and saprophytic syndromes due to Aspergillus spp. Med. Mycol. 2005; 43 (Suppl. 1): S207–S238.

13. Izumikawa K., Tashiro T., Tashiro M. et al. Pathogenesis and clinical features of chronic pulmonary aspergillosis – is it possible to distinguish CNPA and CCPA clinically? J. Infect. Chemother. 2014; 20: 208–212.

14. Kohno S., Izumikawa K., Ogawa K. et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J. Infect. 2010; 61: 410–418.

15. Cadranel J., Philippe B., Hennequin C. et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur. J. Clin. Microbiol. Infect. Dis. 2012; 31: 3231–3239.

16. Kohno S., Masaoka T., Yamaguchi H. et al. A multicenter, openlabel clinical study of micafungin (FK463) in the treatment of deepseated mycosis in Japan. Scand. J. Infect. Dis. 2004; 36: 372–379.

17. Denning D.W., Perlin D.S. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol. 2011; 6: 1229–1232.

18. Denning D.W., Pleuvry A., Cole D.C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med. Mycol. 2013; 51: 361–370.

19. Denning D.W., Pleuvry A., Cole D.C. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur. Respir. J. 2013; 41: 621–626.

20. Stevens D.A., Kan V.L., Judson M.A. et al. Practice guide lines for diseases caused by Aspergillus. Clin. Infect. Dis. 2000; 30: 696–709.

21. Walsh T.J., Anaissie E.J., Denning D.W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 327–360.

22. Ullmann A.J., Cornely O.A., Donnelly J.P. et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin. Microbiol. Infect. 2012; 18: Suppl. 7, 1–8.

23. Dai Z., Zhao H., Cai S. et al. Invasive pulmonary asper gillosis in nonneutropenic patients with and without underlying disease: a singlecentre retrospective analysis of 52 subjects. Respirology. 2013; 18: 323–331.

24. Kim S.Y., Lee K.S., Han J. et al. Semiinvasive pulmonary aspergillosis: CT and pathologic findings in six patients. Am. J. Roentgenol. 2000; 174: 795–798.

25. Kobashi Y., Fukuda M., Yoshida K. et al. Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. Respirology. 2006; 11: 809–813.

26. Kosmidis C., Denning D.W. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015; 70: 270–277.

27. Denning D.W., Follansbee S., Scolaro M. et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1991; 324: 654–662.

28. Kono Y., Tsushima K., Yamaguchi K. et al. The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. Respir. Med. 2013; 107: 1094–1100.

29. Uffredi M.L., Mangiapan G., Cadranel J. et al. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 2003; 22: 457–462.

30. Camuset J., Nunes H., Dombret M.C. et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007; 131: 1435–1441.

31. Nam H.S., Jeon K., Um S.W. et al. Clinical characteris tics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int. J. Infect. Dis. 2010; 14: e479–e482.

32. Horvath J.A., Dummer S. The use of respiratorytract cultures in the diagnosis of invasive pulmonary aspergillosis. Am. J. Med. 1996; 100: 171– 178.

33. McCarthy D.S., Pepys J. Allergic bronchopulmonary aspergillosis. Clinical immunology. 2. Skin, nasal and bronchial tests. Clin. Allergy. 1971; 1: 415–432.

34. Chakrabarti A., Sethi S., Raman D.S.V. et al. Eightyear study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital. Mycoses. 2002; 45: 295–299.

35. Pashley C.H., Fairs A., Morley J.P. et al. Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med. Mycol. 2012; 50: 433–438.

36. Fraczek M.G., Kirwan M.B., Moore C.B. et al. Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. Mycoses. 2014; 57: 69–78.

37. Howard S.J., Cerar D., Anderson M.J. et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 2009; 15: 1068–1076.

38. Izumikawa K., Yamamoto Y., Mihara T. et al. Broncho alveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med. Mycol. 2012; 50: 811–817.

39. Shin B., Koh W.J., Jeong B.H. et al. Serum galactoman nan antigen test for the diagnosis of chronic pulmonary aspergillosis. J. Infect. 2014; 68: 494–499.

40. Franquet T., Mäller N.L., Giménez A. et al. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001; 21: 825–837.

41. Tashiro T., Izumikawa K., Tashiro M. et al. A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn. J. Infect. Dis. 2013; 66: 312–316.

42. van Toorenenbergen A.W. Betweenlaboratory quality control of automated analysis of IgG antibodies against Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 2012; 74: 278–281.

43. Baxter C.G., Denning D.W., Jones A.M. et al. Perfor mance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin. Microbiol. Infect. 2013; 19: E197–E204.

44. Guitard J., Sendid B., Thorez S. et al. Evaluation of a recombinant antigenbased enzyme immunoassay for the diagnosis of noninvasive aspergillosis. J. Clin. Microbiol. 2012; 50: 762–765.

45. Aspergilloma and residual tuberculous cavities – the results of a resurvey. Tubercle. 1970; 51: 227–245.

46. Kitasato Y., Tao Y., Hoshino T. et al. Comparison of Aspergillus galactomannan antigen testing with a new cut off index and Aspergillus precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. Respirology. 2009; 14: 701–708.

47. Ohba H., Miwa S., Shirai M. et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir. Med. 2012; 106: 724–729

48. Brouwer J. Detection of antibodies against Aspergillus fumigatus: comparison between double immunodiffusion, ELISA and immunoblot analysis. Int. Arch. Allergy Appl. Immunol.1988; 85: 244–249.

49. Schønheyder H. Pathogenetic and serological aspects of pulmonary aspergillosis. Scand. J. Infect. Dis. 1987; 51 (Suppl.): 1–62.

50. Ninomiya H., Harada S., Harada Y. et al. [Serological diagnosis of pulmonary aspergillosismeasurement of IgG, IgM and IgAantibodies against Aspergillus fumigatus by means of ELISA]. Kekkaku. 1990; 65: 263–272.

51. Agarwal R., Garg M., Aggarwal A.N. et al. Serologic aller gic bronchopulmonary aspergillosis (ABPAS): longterm outcomes. Respir. Med. 2012; 106: 942–947.

52. McCarthy D.S., Pepys J. Pulmonary aspergillomaclinical immunology. Clin. Allergy. 1973; 3: 57–70.

53. Brummund W., Resnick A., Fink J.N. et al. Aspergillus fumigatusspecific antibodies in allergic bronchopul monary aspergillosis and aspergilloma: evidence for a polyclonal antibody response. J. Clin. Microbiol. 1987; 25: 5–9.

54. Page I.D., Richardson M., Denning D.W. Antibody testing in aspergillosisquo vadis? Med. Mycol. 2015; 52: 417–439.

55. Greene R. The radiological spectrum of pulmonary aspergillosis. Med. Mycol. 2005; 43 (Suppl. 1): S147–S154.

56. Roberts C.M., Citron K.M., Strickland B. Intrathoracic aspergilloma: role of CT in diagnosis and treatment. Radiology. 1987; 165: 123–128.

57. Baxter C.G., Bishop P., Low S.E. et al. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax. 2011; 66: 638–640.

58. Kim J.Y., Yoo J.W., Oh M. et al. (18)Ffluoro2deoxy Dglucose positron emission tomography/computed tomography findings are different between invasive and noninvasive pulmonary aspergillosis. J. Comput. Assist. Tomogr. 2013; 37: 596–601.

59. Felton T.W., Baxter C., Moore C.B. et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin. Infect. Dis. 2010; 51: 1383–1391.

60. Baliko Z., Sarosi V., Illes M.B. et al. PETCT imaging and reality. Pathol. Oncol. Res. 2011; 17: 393–395.

61. Patterson K.C., Strek M.E. Diagnosis and treatment of pulmonary aspergillosis syndromes. Chest. 2014; 146: 1358–1368.

62. Smith N.L., Denning D.W. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur. Respir. J. 2011; 37: 865– 872.

63. Kato T., Usami I., Morita H. et al. Chronic necrotizing pulmonary aspergillosis in pneumoconiosis: clinical and radiologic findings in 10 patients. Chest. 2002; 121: 118–127.

64. Parakh U.K., Sinha R., Bhatnagar A.K. et al. Chronic necrotising pulmonary aspergillosis: a rare complication in a case of silicosis. Indian. J. Chest Dis. Allied. Sci. 2005; 47: 199–203.

65. Blanco J.J., Barcala F.J.G., Moure M.A.A. et al. Aspergilosis pulmonar necrotizante crónica como complicación de silicosis [Chronic necrotising pulmonary aspergillosis as a complication of silicosis]. An. Sist. Sanit. Navar. 2011; 34: 109–114.

66. Lachkar S., Dominique S., Thiberville L. et al. Aspergillose et sarcoїdose [Aspergillosis and sarcoidosis]. Rev. Mal. Respir. 2007; 24: 943–953.

67. Soubani A.O., Chandrasekar P.H. The clinical spectrum of pulmonary aspergillosis. Chest. 2002; 121: 1988–1999.

68. Huang C.W., Lee M.A., Lu R.H. et al. A case of pulmonary aspergilloma and actinomycosis. J. Med. Microbiol. 2011; 60: 543–546.

69. Bal A., Bagai M., Mohan H. et al. Aspergilloma in a pulmonary hydatid cyst: a case report. Mycoses. 2008; 51: 357–359.

70. Pimentel J.C. Pulmonary calcification in the tumorlike form of pulmonary aspergillosis: pulmonary aspergilloma. Am. Rev. Respir. Dis. 1966; 94: 208–216.

71. Park Y., Kim T.S., Yi C.A. et al. Pulmonary cavitary mass containing a mural nodule: differential diagnosis between intracavitary aspergilloma and cavitating lung cancer on contrastenhanced computed tomography. Clin. Radiol. 2007; 62: 227–232.

72. Gazzoni F.F., Severo L.C., Marchiori E. et al. Fungal diseases mimicking primary lung cancer: radiologicpathologic correlation. Mycoses. 2014; 57: 197–208.

73. Adeyemo A.O., Odelowo E.O., Makanjuola D.I. Management of pulmonary aspergilloma in the presence of active tuberculosis. Thorax. 1984; 39: 862–867.

74. Hafeez I., Muers M.F., Murphy S.A. et al. Nontuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis. Thorax. 2000; 55: 717–719.

75. Yoon S.H., Park C.M., Goo J.M. et al. Pulmonary aspergillosis in immunocompetent patients without air meniscus sign and underlying lung disease: CT findings and histopathologic features. Acta. Radiol. 2011; 52: 756–761.

76. Lim J., Lyu J., Choi C.M. et al. Nontuberculous mycobacterial diseases presenting as solitary pulmonary nodules. Int. J. Tuberc. Lung Dis. 2010; 14: 1635–1640.

77. Baik J.J., Lee G.L., Yoo C.G. et al. Pulmonary actinomy cosis in Korea. Respirology. 1999; 4: 31–35.

78. McConnochie K., O’Sullivan M., Khalil J.F. et al. Aspergillus colonization of pulmonary rheumatoid nodule. Respir. Med. 1989; 83: 157–160.

79. Cavazza A., Paci M., Turrini E. et al. Fungus colonisation of pulmonary rheumatoid nodule. J. Clin. Pathol. 2003; 56: 636–637.

80. Denning D.W., Follansbee S.E., Scolaro M. et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1991; 324: 654–662.

81. Rajalingham S., Anshar F.M. Chronic necrotizing pulmonary aspergillosis presenting as bilateral pleural effusion: a case report. J. Med. Case Rep. 2012; 6: 62.

82. Schweer K.E., Wittersheim M., Bangard C. et al. Chronische pulmonale aspergilloses: vier klinische fall beispiele und uberblick uber die aktuelle literatur [Chronic pulmonary aspergillosis: four exemplary clinical cases and literature overview]. Dtsch. Med. Wochenschr. 2014; 139: 2242–2247.

83. Agarwal R., Vishwanath G., Aggarwal A.N. et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses. 2013; 56: 559–570.

84. Jones P.W., Quirk F.H., Baveystock C.M. et al. A self complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321–1327.

85. Alshair K., Atherton G.T.W., Kennedy D. et al. Validity and reliability of the St. George’s Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest. 2013; 144: 623–631.

86. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J. Am. Acad. Dermatol. 1990; 23: 607–614.

87. De Beule K., De Doncker P., Cauwenbergh G. et al. The treatment of aspergillosis and aspergilloma with itracona zole, clinical results of an open international study (1982–1987). Mycoses. 1988; 31: 476–485.

88. Judson M.A., Stevens D.A. The treatment of pulmonary as pergilloma. Curr. Opin. Invest. Drugs. 2001; 2: 1375–1377.

89. Jain L.R., Denning D.W. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J. Infect. 2006; 52: e133–e137.

90. Sambatakou H., Dupont B., Lode H. et al. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am. J. Med. 2006; 119: 527.e17–e24.

91. Saito T., Fujiuchi S., Tao Y. et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection. 2012; 40: 661–667.

92. Cucchetto G., Cazzadori A., Conti M. et al. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series. Infection. 2015; 43: 277–286.

93. Caras W.E., Pluss J.L. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin. Proc. 1996; 71: 25–30.

94. Saraceno J.L., Phelps D.T., Ferro T.J. et al. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest. 1997; 112: 541–548.

95. Camuset J., Lavolé A., Wislez M. et al. [Infections aspergillaires bronchopulmonaires du sujet nonimmun odéprimé [Bronchopulmonary aspergillosis infections in the nonimmunocompromised patient]. Rev. Pneumol. Clin. 2007; 63: 155–166.

96. Yoshida K., Shoji H., Takuma T. et al. Iliopsoas abscess caused by Aspergillus fumigatus complicated by pulmonary aspergillosis. J. Infect. Chemother. 2012; 18: 569–575.

97. Kohno S., Izumikawa K., Yoshida M. et al. A doubleblind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. 2013; 32: 387–397.

98. Yasuda S., Ohnishi R., Suzuki T. et al. [Shortterm efficacy evaluation of chronic pulmonary aspergillosis treated with micafangin and maintenance therapy of itraconazole]. Nihon Kokyuki Gakkai Zasshi. 2009; 47: 985–990.

99. Kohno S., Izumikawa K., Kakeya H. et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med. Mycol. 2011; 49: 688–693.

100. Izumikawa K., Ohtsu Y., Kawabata M. et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med. Mycol. 2007; 45: 273–278.

101. Newton P.J., Harris C., Denning D.W. The clinical response to a shortterm course of intravenous liposomal amphotericin B therapy in patients with chronic pulmonary aspergillosis. Available from: http://www.aspergillus.org. uk/content/clinicalresponseshorttermcourseintravenousliposomalamphotericinbtherapypatients

102. Keir G.J., Garfield B., Hansell D.M. et al. Cyclical caspo fungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax. 2014; 69: 287–288.

103. Newton P.J., Harris C., Denning D.W. The clinical response to a shortterm course of intravenous liposomal amphotericin B therapy in patients with chronic pulmonary aspergillosis. Mycoses. 2013; 56 (Suppl. 3): 164.

104. Rumbak M., Kohler G., Eastrige C. et al. Topical treatment of life threatening haemoptysis from aspergillomas. Thorax. 1996; 51: 253–255.

105. Kravitz J.N., Berry M.W., Schabel S.I. et al. A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest. 2013; 143: 1414–1421.

106. Giron J., Poey C., Fajadet P. et al. CTguided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases. Eur. J. Radiol. 1998; 28: 235–242.

107. Yamada H., Kohno S., Koga H. et al. Topical treatment of pulmonary aspergilloma by antifungals: relationship between duration of the disease and efficacy of therapy. Chest. 1993; 103: 1421–1425.

108. Hargis J.L., Bone R.C., Stewart J. et al. Intracavitary

109. amphotereicin B in the treatment of symptomatic pulmonary aspergillomas. Am. J. Med. 1980; 68: 389–394.

110. Lee K.S., Kim H.T., Kim Y.H. et al. Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. Am. J. Roentgenol. 1993; 161: 727–731.

111. Shapiro M.J., Albelda S.M., Mayock R.L. et al. Severe hemoptysis associated with pulmonary aspergilloma: per cutaneous intracavitary treatment. Chest. 1988; 94: 1225–1231.

112. Munk P.L., Vellet A.D., Rankin R.N. et al. Intracavitary aspergilloma: transthoracic percutaneous injection of amphotericin gelatin solution. Radiology. 1993; 188: 821–823.

113. Jackson M., Flower C.D., Shneerson J.M. Treatment of symptomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter. Thorax. 1993; 48: 928–930.

114. Krakówka M., Traczyk K., Walczak J. et al. Local treatment of aspergilloma of the lung with a paste containing nystatin of amphotericin B. Tubercle. 1970; 51: 184–191.

115. Hendee W.R., Edwards F.M. ALARA and an integrated approach to radiation protection. Semin. Nucl. Med. 1986; 16: 142–150.

116. Rafferty P., Biggs B.A., Crompton G.K. et al. What happens to patients with pulmonary aspergilloma? Analysis of 23 cases. Thorax. 1983; 38: 579– 583.

117. Döffinger R., Harris C., Lear S. et al. Impaired Th1 and Th17 immunity in chronic pulmonary aspergillosis. In: NHS England National Commissiong Group Chronic Pulmonary Aspergillosis national service, The National Aspergillosis Centre Annual Report 2013–2014. NHS England, London; 2014. Available from: http://www.uhsm.nhs.uk/nac/news/Documents/NAC%20annual%20report%2020134%20web.pdf

118. Kelleher P., Goodsall A., Mulgirigama A. et al. Interferonγ therapy in two patients with progressive chronic pulmonary aspergillosis. Eur. Respir. J. 2006; 27: 1307–1310.

119. Prutsky G., Domecq J.P., Salazar C.A. et al. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst. Rev. 2012; 4: CD008711.

120. Moen C.A., Burrell A., Dunning J. Does tranexamic acid stop haemoptysis? Interact. Cardiovasc. Thorac. Surg. 2013; 17: 991–994.

121. Jardin M., Remy J. Control of hemoptysis: systemic angiography and anastomoses of the internal mammary artery. Radiology. 1988; 168: 377– 383.

122. Swanson K.L., Johnson C.M., Prakash U.B.S. et al. Bronchial artery embolization: experience with 54 patients. Chest. 2002; 121: 789–795.

123. Corr P. Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization. Cardiovasc. Intervent. Radiol. 2006; 29: 807–810.

124. Serasli E., Kalpakidis V., Iatrou K. et al. Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and longterm outcomes. Int. Angiol. 2008; 27: 319–328.

125. Brik A., Salem A.M., Kamal A.R. et al. Surgical outcome of pulmonary aspergilloma. Eur. J. Cardiothorac. Surg. 2008; 34: 882–885.

126. Farid S., Mohamed S., Devbhandari M. et al. Results of surgery for chronic pulmonary aspergillosis, optimal antifungal therapy and proposed high risk factors for recur rence – a National Centre’s experience. J. Cardiothorac. Surg. 2013; 8: 180.

127. Regnard J.F., Icard P., Nicolosi M. et al. Aspergilloma: a series of 89 surgical cases. Ann. Thorac. Surg. 2000; 69: 898–903.

128. Kim Y.T., Kang M.C., Sung S.W. et al. Good longterm outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann. Thorac. Surg. 2005; 79: 294–298.

129. Pratap H., Dewan R.K., Singh L. et al. Surgical treatment of pulmonary aspergilloma: a series of 72 cases. Indian. J. Chest Dis. Allied. Sci. 2007; 49: 23–27.

130. Muniappan A., Tapias L.F., Butala P. et al. Surgical therapy of pulmonary aspergillomas: a 30year North American experience. Ann. Thorac. Surg. 2014; 97: 432–438.

131. Lejay A., Falcoz P.E., Santelmo N. et al. Surgery for aspergilloma: time trend towards improved results? Interact. Cardiovasc. Thorac. Surg. 2011; 13: 392–395.

132. Chen Q.K., Jiang G.N., Ding J.A. Surgical treatment for pulmonary aspergilloma: a 35year experience in the Chinese population. Interact. Cardiovasc. Thorac. Surg. 2012; 15: 77–80.

133. Chen Q.K., Chen C., Chen X.F. et al. Videoassisted thoracic surgery for pulmonary aspergilloma: a safe and effective procedure. Ann. Thorac. Surg. 2014; 97: 218–223.

134. Igai H., Kamiyoshihara M., Nagashima T. et al. Pulmonary aspergilloma treated by limited thoracoplasty with simultaneous cavernostomy and muscle transposition flap. Ann. Thorac. Cardiovasc. Surg. 2012; 18: 472– 474.

135. Grima R., Krassas A., Bagan P. et al. Treatment of complicated pulmonary aspergillomas with cavernostomy and muscle flap: interest of concomitant limited thoracoplasty. Eur. J. Cardiothorac. Surg. 2009; 36: 910–913.

136. Srivastava D.N., Jana M., Bhalla A. et al. Bronchial artery embolization in pulmonary diseases: current scenario. J. Int. Med. Sci. Acad. 2013; 26: 69–71.

137. Stather D.R., Tremblay A., MacEachern P. et al. Bron choscopic removal of a large intracavitary pulmonary aspergilloma. Chest. 2013; 143: 238–241.

138. Stather D., Tremblay A., MacEachern P. et al. Intra cavitary pulmonary aspergilloma removal using combined virtual, ultrathin, and rigid bronchoscopy – a case series. Chest. 2013; 144: 817A.

139. Akbari J.G., Varma P.K., Neema P.K. et al. Clinical profile and surgical outcome for pulmonary aspergilloma: a single center experience. Ann. Thorac. Surg. 2005; 80: 1067– 1072.

140. Sagan D., Goz′dziuk K. Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy. Ann. Thorac. Surg. 2010; 89: 1603–1610.

141. Benhamed L., Woelffle D. Adjuvant antifungal therapy after pulmonary surgery for aspergilloma: is it useful? Interact. Cardiovasc. Thorac. Surg. 2014; 18: 835–837.

142. Muldoon E.G., Page I., Bishop P. et al. Aspergillus pulmonary nodules; presentation, radiology, and histology features. In: NHS England National Commissiong Group Chronic Pulmonary Aspergillosis national service, The National Aspergillosis Centre Annual Report 2013–2014. NHS England, London; 2014. Available from: http://www.uhsm.nhs.uk/nac/news/Documents/NAC%20annual%20re

143. port%2020134%20web.pdf